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Abstract
Following the introduction of non-invasive positive pressure ventilation (NPPV), the number of patients using home mechanical
ventilation has increased substantially and continues to rise worldwide. This is primarily explained by both the effectiveness and
comfort that are offered by NPPV in most patients, and particularly in patients with chest wall and neuromuscular diseases. For
clinically stable patients the qualification for NPPV largely depends on the presence of complaints or signs of (nocturnal) hypoventilation
with accompanying hypercapnia. For patients who are referred by an ICU there are additional prerequisites. In any case, the aims of
NPPV should be met and NPPV should be effective. The initiation of NPPV, whether in the clinic or not, should always be tailored to the
individual patient. Based on effectiveness, safety, and comfort, the best ventilator has to be chosen. Although with modern interfaces
NPPV may be provided continuously, for continuing NPPV over the years, adding manual and/or mechanical cough augmentation
techniques is usually mandatory. To control the ongoing effectiveness of NPPV regular monitoring of the patient is essential, and
nowadays transcutaneous measurement of CO2 seems the most reliable and appropriate technique. For trend analysis, downloaded
data of modern ventilators may be helpful as well. The ultimate goal of NPPV, to prevent tracheotomy, can only be reached if the
patient has continuous access to a centre with expertise in cough augmentation techniques and both nocturnal and diurnal NPPV.
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Streszczenie
Wprowadzenie nieinwazyjnej wentylacji mechanicznej (NWM) zwiększyło liczbę chorych korzystających z wentylacji mecha-
nicznej w domu. Liczba ta stale rośnie na całym świecie. Jest to spowodowane przede wszystkim skutecznością i komfortem
NWM u większości chorych, szczególnie u tych ze schorzeniami klatki piersiowej oraz chorobami nerwowo-mięśniowymi.
U chorych stabilnych klinicznie kwalifikacja do NWM opiera się na dolegliwościach zgłaszanych w wywiadach i objawach nocnej
hipowentylacji z towarzyszącą hiperkapnią. Pacjenci kierowani z oddziału intensywnej opieki medycznej muszą spełniać jeszcze
inne kryteria. W każdym przypadku cele NWM powinny być spełnione i NWM powinna być skuteczna. Rozpoczęcie NWM
zarówno w klinice, jak i poza nią musi być dostosowane do indywidualnych potrzeb pacjenta. W celu osiągnięcia skuteczności,
bezpieczeństwa i komfortu należy wybrać najlepszy respirator. Dzięki wykorzystaniu nowoczesnej maski NWM może być
stosowana w sposób ciągły przez lata, chociaż zazwyczaj wymaga wspomagania kaszlu (ręcznego lub mechanicznego). Aby
ocenić skuteczność NWM, konieczne jest monitorowanie chorego. Obecnie przezskórny pomiar CO2 wydaje się najbardziej
odpowiednią techniką. Podczas długotrwałych obserwacji uzyskane dane powinny być wprowadzone do pamięci respiratora.
Ostateczny cel NWM, którym jest uniknięcie tracheotomii, może zostać osiągnięty, jeśli pacjent ma zapewniony stały dostęp do
centrum, które ma doświadczenie w technikach wspomagania kaszlu oraz nocnej i dziennej NWM.
Słowa kluczowe: nieinwazyjna wentylacja, kwalifikacja, rozpoczęcie, monitorowanie
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Introduction
Non-invasive ventilation has been used as
early as in the 1800s, but its true advance occur-
red during the polio epidemics in the first half of
the 20th century by means of so-called tank venti-
lators, including the ‘iron lung’ [1]. In the late 1950s
and 1960s the obvious advantages of invasive po-
sitive pressure ventilation led, however, to the vir-
tual substitution of non-invasive ventilation tech-
niques. Interest in non-invasive ventilation began
to reappear during the mid 1980s, following the
development of a nasal mask for applying conti-
nuous positive airway pressure (CPAP) in patients
with obstructive sleep apnoea [2]. Soon after, re-
ports began emerging of the positive effects of non-
invasive positive pressure ventilation (NPPV) in
patients with acute or chronic respiratory failure
[3, 4]. From then on things went very fast. Impro-
vements in both ventilators and interfaces have
given NPPV a central role nowadays in the care of
patients with chronic respiratory failure [5]. In this
article three core aspects of NPPV will be discus-
sed: qualification, initiation, and monitoring.
Qualification
In order to qualify for chronic NPPV patients
should have a disease that causes both chronic re-
spiratory failure and complaints and/or signs of
nocturnal hypoventilation, like restless sleep, ni-
ghtmares, night sweating, morning headaches,
awaking not fit, failure to thrive, difficulty in con-
centrating, hypersomnolence, orthopnoea, weight
loss, and tachypnoea. Recurrent chest infections
may be caused by both (nocturnal) hypoventilation
and decreased coughing strength. Sitting and su-
pine lung function tests, though helpful in detec-
ting progress of weakness of the respiratory musc-
les and frequently predictive of nocturnal hypoven-
tilation, are hardly relevant to qualify for NPPV [6].
In addition, patients should have nocturnal hypo-
ventilation or, in a later stage of their disease, chro-
nic respiratory failure, in terms of hypercapnia
(PCO2 > 45 mm Hg or > 6.0 kPa) (Tab. 1). As 70% of
patients with nocturnal hypoventilation will develop
daytime hypercapnia or secondary complications
within one year, it seems prudent to start NPPV once
nocturnal hypoventilation is demonstrated [7–9]. In
patients with amyotrophic lateral sclerosis (ALS) hy-
percapnia is not always required to qualify for NPPV,
as these patients may have normocapnia at the cost of
high work of breathing or are likely to develop (noc-
turnal) hypercapnia within days or weeks. Even wi-
thout demonstrable hypercapnia these patients may,
however, experience benefit from NPPV.
Patients should also meet the aims of NPPV:
maintaining or improving the quality of life with
increased independence, exercise tolerance, and
better communication; preventing secondary com-
plications like recurrent chest infections and cor
pulmonale; and increasing survival [8]. In addition,
NPPV should be effective, as shown by an impro-
vement of ventilation, gas exchange, and sleep
quality and quantity, and by a reduction of com-
plaints and symptoms [9]. These aims are usually
met in patients with neuromuscular diseases and
chest wall disorders. In patients with chronic ob-
structive pulmonary disease (COPD), however, it
is still uncertain if these goals can be reached. For
COPD patients with chronic respiratory failure in
general, several randomized controlled trials have
not shown a clear benefit of NPPV, in terms of
improved survival or quality of life [10–12]. In the
Netherlands, NPPV is thus only offered to COPD pa-
tients with chronic respiratory failure as a bridge to
transplant [13]. Conceivably, continuation of NPPV
in the home setting may be beneficial to a subgro-
up of COPD patients who used acute NPPV during
recurrent hospital admissions for hypercapnic exa-
cerbations [14, 15]. This is at present being investi-
gated in three randomized controlled trials, which
are running in France, the UK, and the Netherlands.
Until the results of these trials are published, a ra-
ther restrictive policy with regard to domiciliary use
of NPPV in patients with COPD seems justified.
Table 1. Diseases and level of (nocturnal) hypercapnia for which NPPV may be indicated, depending on the presence
or absence of complaints of nocturnal hypoventilation
Tabela 1. Wskazania do NPPV w zależności od schorzenia, stężenia dwutlenku węgla oraz objawów nocnej hipowentylacji
Without complaints With complaints
Neuromuscular disease > 7.0 kPa (52.5 mm Hg) > 6.0 kPa (45.0 mm Hg)
Motor neuron disease > 6.0 kPa (45.0 mm Hg) Irrespective of PCO2
Chest wall disorder > 7.0 kPa (52.5 mm Hg) > 6.0 kPa (45.0 mm Hg)
Obesity hypoventilation syndrome > 7.5 kPa (56.3 mm Hg) > 7.5 kPa (56.3 mm Hg)
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Finally, there are a number of prerequisites
that have to be met, particularly by patients on an
intensive care unit (ICU), before home mechani-
cal ventilation (HMV) in general can be conside-
red [16–18]. There should be no other options to
treat the respiratory failure, like medication, oxy-
gen therapy, or CPAP. Reversible factors, for exam-
ple electrolyte disturbances, heart failure, consti-
pation, and medication causing depressed respi-
ratory drive, should be corrected. Patients should
be clinically stable as shown by, amongst other
things, an inspiratory oxygen fraction £ 0.4 and a
positive end-expiratory pressure £ 10 cm H2O. If
possible, they should have been weaned, but not
at the expense of severe hypercapnia. Weaning is
not only important to determine the need for long-
term ventilation but also to estimate the ventila-
tor-free time, which is important for reasons of
safety. Although weaning itself is not a prerequ-
isite for NPPV, the chance of success of transfer-
ring patients from invasive ventilation to NPPV
seems, to some extent, related to ventilator depen-
dency. NPPV should not be futile, which denotes
that patients should have a life expectancy of se-
veral months at least. Moreover, patients must be
motivated to use NPPV and they should also have
a clear perspective for using it for some time, and
often indefinitely. Last but not least, the home si-
tuation should be safe or adapted to be safe with
regard to the physical environment, basic utilities
(electricity, heating), alarms, and adequate resour-
ces, both financially and with regard to the num-
ber of competent caregivers. The latter is usually
only considered for patients using invasive venti-
lation, but patients fully dependent on NPPV may
also need more care than the care of family mem-
bers and lay helpers, also depending on the nature
of their underlying disease.
Initiation
Preferably, NPPV should be initiated elective-
ly in a quiet atmosphere without pressure on the
patient. All equipment and expertise should, ide-
ally, be available to make NPPV both effective and
comfortable in the shortest time. For this reason,
initiating NPPV in the home setting of a patient
may be difficult but not impossible. Randomised
controlled trials showed comparable results betwe-
en in- and outpatient initiation of NPPV in highly
selected patients with neuromuscular disease and
near normal daytime PaCO2, but without bulbar
weakness or cognitive impairment [19, 20]. At pre-
sent, the initiation of NPPV is usually performed
on respiratory wards or respiratory care units.
To be ventilated, a patient needs an interface
and a ventilator, which either operates in the vo-
lume controlled mode or in the pressure control-
led mode. In the volume controlled mode, a fixed
volume is delivered during a specified time with
any pressure that is necessary to achieve this, re-
gardless of the patient’s own ventilation [21]. An
inspiratory effort will thus not lead to changes in
the delivered volume, but only result in a lower
airway pressure. The advantage of this modality
is, in the absence of leaks, the fixed delivery of the
preset volume, irrespective of the compliance and
resistance of the respiratory system. If there is
a leak, however, there will be no increase in flow
rate to compensate for it and the volume effective-
ly delivered will be diminished.
In the pressure-controlled mode, airflow is
delivered by generating a predefined positive pres-
sure in the airways for a given time [21]. Constant
analysis of the flow rate and airway pressure de-
termines the flow variations necessary to keep
a certain pressure. Consequently, the volume de-
livered will depend on the interaction between the
preset pressure, the inspiratory time, the complian-
ce and resistance of the respiratory system, and the
inspiratory efforts of the patient. To overcome this
limitation, some new ventilators adjust the pres-
sure level within each cycle or during several cyc-
les to provide a preset target volume, thus combi-
ning features of pressure and volume ventilation.
This hybrid mode is called volume-targeted pres-
sure ventilation [21]. This mode may improve noc-
turnal ventilation, particularly in patients with
obesity hypoventilation syndrome [22].
For NPPV, most of the time a pressure-control-
led ventilator is chosen as this type of ventilator is
able to compensate for moderate leaks. There is,
however, no proof that pressure-controlled venti-
lation is in general better than volume-controlled
ventilation [9, 23, 24]. For each individual patient
the best ventilator has to be chosen based on ef-
fectiveness, safety, and comfort. Modern (hybrid)
ventilators, instead of offering only one mode of
ventilation, have several modes of ventilation.
Besides a volume-controlled mode, they may offer
a pressure support mode and a pressure-control-
led mode, with or without a target volume. In ad-
dition, they may have the option of positive end-
expiratory pressure (PEEP or EPAP), and they may
be used with both an open system, like BiPAP, and
a closed system with an expiratory valve. In seve-
ral machines, two or even three profiles are ava-
ilable for different ventilatory modes and needs.
Several of these ‘all-in-one’ ventilators offer the
possibility of a tubing system with one or two ho-
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ses. Finally, this new generation of ventilators has
the possibility of storing ventilatory data for up to
a year and to combine these with data from ano-
ther source, like a pulse oximeter or capnometer.
Foremost in neuromuscular patients, the set-
tings of the ventilator should be set with the aim
to control (nocturnal) ventilation, to reduce CO2,
and preferably to reach normocapnia or an accep-
table PaCO2 if normocapnia cannot be reached or
is not desired (COPD), and thus reach the aims of
NPPV [9, 25]. Simultaneously with striving for
normocapnia, the least number of hours on the
ventilator should be aimed for. Consequently, noc-
turnal ventilation needs to be optimally effective
before the number of hours on the ventilator du-
ring daytime is extended. Furthermore, by aiming
for effective ventilation, supplemental oxygen the-
rapy may be reduced or stopped and PEEP-levels
can be minimized.
At the same time, the patient has to accept and
tolerate an interface [26–28]. For patients with
claustrophobia, interfaces with a small nose cap
or nasal pillows, which hardly cover the face, may
be a solution. Once the patient tolerates the inter-
face and feels comfortable sleeping with it, the ef-
fectiveness comes into play. Guidelines or practi-
ce standards stating the best interface for each pa-
tient do not exist. Finding the best interface is
a matter of trial and error. In most patients a nasal
mask will do. A nasal mask offers comfort and al-
lows for speech and verbal alarms but may cause
a leak through the mouth during sleep, which may
reduce the quality of ventilation and sleep [29].
If there is a serious leak through the mouth
despite a chinstrap, a nose-mouth (full face) mask
may be an option [30]. This is often necessary in
patients with a low respiratory compliance, like
those with chest wall disorders or obesity hypo-
ventilation syndrome. If both a chinstrap and a full-
face mask are not tolerated, humidification may
diminish the leak [31].
A hybrid mask combines nasal pillows, which
fit into the nares, with a mask that covers the mo-
uth. It may be used in case of (imminent) decubi-
tus of the nasal bridge or for reading or watching
television during the daytime while a conventio-
nal mask is used during the night.
A total face mask, which is often used for acute
NPPV, may be used when other interfaces are not
an option. Because of the large dead space and
suboptimal fit with a large air leak, a very high flow
is usually needed. Some ventilators may not be able
to provide such a high flow.
Nowadays, there is such a wide array of inter-
faces that it is seldom necessary to use a custom
mask. The latter may be made of silicon paste or
may be ordered through companies that speciali-
se in making these, often very nice but expensive,
masks. Whatever mask is chosen, patients should
always have a spare mask at home in case a mask
becomes damaged. For patients needing more than
just nocturnal ventilation, two different masks may
be needed to prevent decubitus on the nasal brid-
ge: for example a full face mask during the night
and a mask with pillows, which leaves the nasal
bridge free, one or more times during the day.
If a patient cannot breathe spontaneously for
more than a few hours at a time, diurnal mouth-
piece ventilation may become an option [32, 33].
The success of continuous NPPV depends on more
than sufficient levels of alveolar ventilation with
different interfaces and ventilators, however.
As most patients using NPPV, and particular-
ly those with neuromuscular disease, also have
cough impairment due to respiratory muscle we-
akness, supporting the inspiratory muscles only is
not enough. Without cough augmentation techni-
ques many patients will have airways encumbe-
red by secretions, which may result in reduced
ventilation and contribute to low ventilation/
/perfusion states, which in turn may cause resorp-
tion atelectasis and shunting. Moreover, retained
secretions may increase the risk of chest infections
and respiratory failure [9, 17, 34]. In addition, the
effectiveness of their NPPV may be impaired by the
diminishing compliance of the respiratory system,
causing insufficient alveolar ventilation [35]. To
overcome these potential problems manual and
mechanical cough augmentation techniques may
be helpful. These techniques include inspiratory
muscle aids, such as hyperinflation via air stacking
or glossopharyngeal breathing; expiratory muscle
aids, such as manually or mechanically assisted
cough; and combined inspiratory and expiratory
muscle aids [36–38].
Air stacking with a resuscitator balloon or
a (volume controlled) ventilator may improve peak
cough flows and prevent decreasing the complian-
ce of the respiratory system. In adults air stacking
is indicated for a peak cough flow (PCF) < 270 L/
/min or a VC < 1.5 L or < 50% predicted [9, 17].
This technique should be practiced three times
a day (reaching five maximal insufflations each time)
and more often during chest infections. The effec-
tiveness of air stacking may be improved by com-
bining this technique with manual thoracic or ab-
dominal-thoracic compression. Glossopharyngeal
breathing, besides improving peak cough flows,
may also be helpful for extending ventilator-free
time [36]. In the absence of unconsciousness and
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barotrauma risk, mechanical insufflation-exsuffla-
tion is recommended when manually assisted co-
ughing and air stacking are no longer effective,
particularly during chest infections, thus preven-
ting the need for tracheostomy [17, 39, 40]. The
latter should be the ultimate goal of NPPV. To keep
patients on NPPV it is usually mandatory to apply
diurnal mouthpiece ventilation and cough au-
gmentation techniques in due time.
Monitoring
To monitor the effectiveness, comfort, and side
effects of domiciliary NPPV, patients should be
visited by a nurse with experience in HMV. In sta-
ble patients 1–2 visits per year are usually suffi-
cient. Children and patients with ALS may need
more frequent visits, however. Patients should also
be given the opportunity to call an experienced
nurse during daily office hours and to visit an out-
patient clinic for HMV patients [41]. Particularly,
patients with continuous NPPV should have con-
tinuous (24/7) access to a centre with expertise in
both nocturnal and diurnal NPPV [42]. Besides
continuous accessibility and availability of expe-
rienced caregivers, there should also be continu-
ous technical support from the company that pro-
vided the ventilator(s) [43]. Finally, the effective-
ness of NPPV may be monitored in the clinic or at
home by means of pulse oximetry, capnometry,
and ventilator data.
Pulse oximetry has the benefits of simplicity,
short set-up time, and short time response (se-
conds) but the drawbacks of motion artefacts, sen-
sitivity to perfusion, and decreased measurement
accuracy at SaO2 < 80% [44]. Furthermore, pulse
oximetry is unreliable for the detection of hypo-
ventilation, particularly in patients with oxygen
supplementation [45]. Though pulse oximetry may
be advocated as a screening tool in stable NPPV
patients without supplemental oxygen, it is unsu-
itable for proper evaluation of domiciliary NPPV,
even when combined with daytime blood gases
[42]. Pulse oximetry may be used, however, to de-
tect hypoxemia caused by airway secretions and
imminent chest infections [17, 34].
For evaluation of the adequacy of alveolar ven-
tilation during NPPV, assessment of PaCO2 is es-
sential, and repeated sampling of arterial blood
remains the ‘gold standard’ [26]. However, repeated
sampling of arterial or capillary blood will usual-
ly cause the patient to awake. The use of an arte-
rial line will generally prevent this but needs spe-
cially trained personnel and a special care setting,
which often are not available for these patients.
Blood for measuring PaCO2 at the end of the night
is often sampled after arousal and thus after a short
period of daytime ventilation. A normal morning
PaCO2 does not, therefore, exclude nocturnal hy-
poventilation. In addition, blood gases reflect gas
exchange at only one point in time and may miss
significant changes in CO2 between measurements.
As invasive assessment of PaCO2 seems inappro-
priate for routine evaluation in stable patients, non-
invasive assessment by measuring transcutaneous
carbon dioxide tension (PtcCO2) or end-tidal car-
bon dioxide tension (PETCO2) may be used [42, 44].
PETCO2 is measured with a capnometer,
which can store data from a whole night. The rela-
tionship between PETCO2 and PaCO2 depends on the
physiological dead space and the tidal volume deli-
vered. The former depends on the type and extent of
underlying disease; the latter on the ventilatory mode
and sleep stage. Non-intentional leaks and varying
alveolar ventilation may also influence PETCO2.
Consequently, PETCO2 measurements during NPPV
are unreliable and should not be used for nocturnal
monitoring of these patients [44, 46].
To monitor PaCO2 in patients with NPPV,
transcutaneous measurement of CO2 seems more
appropriate [42, 44, 47]. By inducing local hype-
raemia of the skin, the capillary blood is ‘arteriali-
zed’ and the permeability of the skin to gas diffu-
sion is improved. The resulting PtcCO2 readings,
which are corrected for both skin and patient tem-
perature, are close to PaCO2 values, without indu-
cing local skin reactions or skin burns. Continu-
ous PtcCO2 recordings have shown to be in good
agreement with arterial measurements, even with
high PaCO2 values [46]. However, all PtcCO2 sen-
sors have a lag time of about two minutes, thus
precluding monitoring of swift changes in PaCO2,
which might be caused by apnoeas, hypopnoeas,
or short-lasting leaks. Other disadvantages of trans-
cutaneous capnometry are the need for periodic
recalibration, sensor drift, and high costs compa-
red to PETCO2 measurements. Nonetheless, noc-
turnal PtcCO2 measurements should be considered
as a reliable tool for monitoring PaCO2 in patients
using NPPV [44, 48, 49].
Modern ventilators are able to store raw data
with respect to airflow and pressure. These data
may be downloaded with built-in software and,
thereby, provide information with regard to tidal
volume, respiratory frequency, minute volume,
triggering, leaks, and patient compliance. In ad-
dition, these data can be analysed during a certa-
in time span or even cycle by cycle. Some venti-
lators have the option of reading external poly-
graphic data on heart rate, SpO2 and PETCO2 or
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PtcCO2. The information thus gathered should be
regarded as indicators of trends only, as the vali-
dity of these parameters still needs to be determi-
ned [44].
Whatever means are used for monitoring pa-
tients on NPPV, the monitoring should always be
done overnight and preferably also during the day-
time, both at rest and during activities. To deter-
mine the amount of hours a patient should use the
ventilator, monitoring should not only occur du-
ring ventilation but also during spontaneous ven-
tilation. Depending on the underlying disease and
other factors that might influence the stability of
the ventilation, monitoring should be performed
2–4 times per year at least. This may be accompli-
shed by visiting patients, by sending cards with
stored data, or by telemedicine [50]. The latter se-
ems attractive, particularly for patients in need of
frequent monitoring and for those living in remo-
te areas.
Conclusions
The introduction of NPPV has caused a silent
yet highly successful revolution in patients with
chronic respiratory failure, particularly in patients
with neuromuscular and chest wall disease. For
NPPV to be successful, qualification criteria sho-
uld be strictly followed, initiation should occur
electively with availability of expertise and all equ-
ipment, carbon dioxide should be reduced, and the
ongoing effectiveness of NPPV should be regular-
ly monitored. The ultimate goal of NPPV, to pre-
vent the need for tracheotomy, can only be reached
if diurnal mouthpiece ventilation and cough au-
gmentation techniques are applied in due time,
meanwhile offering the patient continuous access
to a centre with expertise in both nocturnal and
diurnal NPPV.
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